In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $15.05.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 18.5% and a 34.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $39.80.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $31.50 and a one-year low of $5.12. Currently, Anavex Life Sciences has an average volume of 845.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More on AVXL:
